Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Nadofaragene Firadenovec

1 clinical trial

3 indications

Indication
Bladder Cancer
Indication
Ta/T1
Indication
CIS
Clinical trial
A Phase 4, Multi-center, Open Label Trial to Evaluate Efficacy of Retreatment With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose
Status: Not yet recruiting, Estimated PCD: 2026-07-31